{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:48Z","timestamp":1787017908381,"version":"build-2736575974"},"reference-count":13,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Ipilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab is currently approved in the U.S. and Europe for the treatment of metastatic melanoma in the first- and second-line treatment. Treatment with ipilimumab is linked to immune-related adverse events (irAEs) occurring in the majority of patients. These specific AEs include dermatitis, gastrointestinal disorders (diarrhea, colitis), hepatitis, hypophysitis, hypothyroidism, neuropathy, and iritis\/inflammation of the ciliary body. &lt;b&gt;&lt;i&gt;Case Report:&lt;\/i&gt;&lt;\/b&gt; We report a case of febrile neutropenia with agranulocytosis in the blood smear of a 35-year-old metastatic melanoma patient treated with ipilimumab 3 mg\/kg. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; This AE was probably caused by antineutrophil antibodies associated with ipilimumab treatment. To our knowledge this is the first case report of febrile neutropenia in a metastatic melanoma patient treated with ipilimumab 3 mg\/kg.<\/jats:p>","DOI":"10.1159\/000377650","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T04:23:51Z","timestamp":1424751831000},"page":"105-108","source":"Crossref","is-referenced-by-count":25,"title":["Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report"],"prefix":"10.1159","volume":"38","author":[{"given":"Sebastian","family":"Wo\u017aniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Mackiewicz-Wysocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Krokowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Kwinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2015,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2010.974"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31819aa40b"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07568.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq196"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.11.7316"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2132"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/377650","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/377650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:45:19Z","timestamp":1745415919000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000377650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000377650","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}